Genentech Oncology
TRK=tropomyosin receptor kinase; NTRK=neurotrophic tyrosine receptor kinase.
Tumors that undergo MSI testing can be classified as7:
For colon cancer, NCCN Guidelines® consider IHC for mismatch repair (MMR) and DNA analysis for MSI to be different assays measuring different biological effects caused by deficient MMR function.8
PCR-based MSI testing can be conducted in combination with MMR IHC13
NGS-based MSI testing enables massive parallel sequencing of MMR genes8
Investigators identified over 386,000 microsatellite repeats in a recent study retrospectively analyzing 7,919 exomes and 1,000 whole genomes from The Cancer Genome Atlas (TCGA)12
The graph shows the frequency of MSI-H samples from the 16 most prevalent tumor types in the dataset.
*MSI-H predicted at a confidence level of 0.75.12
IHC=immunohistochemistry; MMR=mismatch repair; MSI=microsatellite instability; MSI-H=MSI-high; MSI-L=MSI-low; MSS=microsatellite stable; NCCN=National Comprehensive Cancer Network; NGS=next-generation sequencing; PCR=polymerase chain reaction.
TMB has been determined using both broad and targeted panels and detected by mutational load in cfDNA samples and liquid biopsies.17-20
TMB=tumor mutational burden.
The relationship between TMB and microsatellite instability (MSI), both markers of genetic instability, was evaluated for 62,150 tumor samples.15
Mb=megabases.
Republished with permission of Nature Publishing Group, from Lawrence MS, et al. Nature. 2013;499(7457):214-218; permission conveyed through Copyright Clearance Center, Inc.
High levels of somatic mutations within tumor cells may result in expression of neoantigens that can induce a T cell response.23
Increased mutation burden may be associated with a higher number of antigens, which may result in greater tumor immunogenicity.9,12,23,24
The biologic rationale behind TMB’s potential as a biomarker is that tumors with high TMB are likely to accumulate neoantigens, making the tumors susceptible to activated immune cells.9,24
cfDNA=circulating free DNA; NGS=next-generation sequencing; TMB=tumor mutational burden.
Murphy DA, et al. Detecting gene rearrangements in patient populations through a 2-step diagnostic test comprised of rapid IHC enrichment followed by sensitive next-generation sequencing. Appl Immunohistochem Mol Morphol. 2017;25(7):513-523.
Murphy DA, et al. Detecting gene rearrangements in patient populations through a 2-step diagnostic test comprised of rapid IHC enrichment followed by sensitive next-generation sequencing. Appl Immunohistochem Mol Morphol. 2017;25(7):513-523.
Vaishnavi A, Le AT, Doebele RC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov. 2015;5(1):25-34.
Vaishnavi A, Le AT, Doebele RC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov. 2015;5(1):25-34.
Su D, et al. High performance of targeted next generation sequencing on variance detection in clinical tumor specimens in comparison with current conventional methods. J Exp Clin Cancer Res. 2017;36(1):121.
Su D, et al. High performance of targeted next generation sequencing on variance detection in clinical tumor specimens in comparison with current conventional methods. J Exp Clin Cancer Res. 2017;36(1):121.
Hechtman JF, et al. Pan-Trk immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions. Am J Surg Pathol. 2017;41(11):1547-1551.
Hechtman JF, et al. Pan-Trk immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions. Am J Surg Pathol. 2017;41(11):1547-1551.
Stack EC, Wang C, Roman KA, Hoyt CC. Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of tyramide signal amplification, multispectral imaging and multiplex analysis. Methods. 2014;70(1):46-58.
Stack EC, Wang C, Roman KA, Hoyt CC. Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of tyramide signal amplification, multispectral imaging and multiplex analysis. Methods. 2014;70(1):46-58.
Rogers TM, et al. Multiplexed transcriptome analysis to detect ALK, ROS1 and RET rearrangements in lung cancer. Sci Rep. 2017;7:42259.
Rogers TM, et al. Multiplexed transcriptome analysis to detect ALK, ROS1 and RET rearrangements in lung cancer. Sci Rep. 2017;7:42259.
Richman S. Deficient mismatch repair: read all about it. Int J Oncol. 2015;47(4):1189-1202.
Richman S. Deficient mismatch repair: read all about it. Int J Oncol. 2015;47(4):1189-1202.
Referenced from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Colon Cancer V.4.2020. © National Comprehensive Cancer Network, Inc 2020. All rights reserved. Accessed June 15, 2020. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
Referenced from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Colon Cancer V.4.2020. © National Comprehensive Cancer Network, Inc 2020. All rights reserved. Accessed June 15, 2020. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
Le DT, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509-2520.
Le DT, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509-2520.
Peltomäki P. Update on Lynch syndrome genomics. Fam Cancer. 2016;15(3):385-393.
Peltomäki P. Update on Lynch syndrome genomics. Fam Cancer. 2016;15(3):385-393.
Vilar E, et al. Microsatellite instability in colorectal cancer—the stable Evidence. Nat Rev Clin Oncol. 2010;7(3):153–162.
Vilar E, et al. Microsatellite instability in colorectal cancer—the stable Evidence. Nat Rev Clin Oncol. 2010;7(3):153–162.
Cortes-Ciriano I, et al. A molecular portrait of microsatellite instability across multiple cancers. Nat Commun. 2017;8:15180.
Cortes-Ciriano I, et al. A molecular portrait of microsatellite instability across multiple cancers. Nat Commun. 2017;8:15180.
Boyle TA, Bridge JA, Sabatini LM, et al. Summary of microsatellite instability test results from laboratories participating in proficiency surveys: proficiency survey results from 2005 to 2012. Arch Pathol Lab Med. 2014;138(3):363-370.
Boyle TA, Bridge JA, Sabatini LM, et al. Summary of microsatellite instability test results from laboratories participating in proficiency surveys: proficiency survey results from 2005 to 2012. Arch Pathol Lab Med. 2014;138(3):363-370.
US Food and Drug Administration. https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019C.pdf. Accessed December 12, 2019.
US Food and Drug Administration. https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019C.pdf. Accessed December 12, 2019.
Chalmers ZR, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34.
Chalmers ZR, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34.
Tran E, et al. ‘Final common pathway’ of human cancer immunotherapy: targeting random somatic mutations. Nat Immunol. 2017;18(3):255-262.
Tran E, et al. ‘Final common pathway’ of human cancer immunotherapy: targeting random somatic mutations. Nat Immunol. 2017;18(3):255-262.
Roszik J, et al. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Med. 2016;14(1):168.
Roszik J, et al. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Med. 2016;14(1):168.
Clinical implications of circulating tumor DNA tumor mutational burden (ctDNA TMB) in non-small cell lung cancer. Oncologist. 2019;24(6):820-828.
Clinical implications of circulating tumor DNA tumor mutational burden (ctDNA TMB) in non-small cell lung cancer. Oncologist. 2019;24(6):820-828.
Tumor mutational burden (TMB) in plasma from mCRPC patients using two commercial NGS assays. Sci Rep. 2019:14;9(1):114. doi: 10.1038/s41598-018-37128-y.
Tumor mutational burden (TMB) in plasma from mCRPC patients using two commercial NGS assays. Sci Rep. 2019:14;9(1):114. doi: 10.1038/s41598-018-37128-y.
Koeppel F, et al. Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients. PLoS One. 2017;12:e0188174.
Koeppel F, et al. Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients. PLoS One. 2017;12:e0188174.
Lawrence MS, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214-218.
Lawrence MS, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214-218.
Rizvi NA, et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer. Science. 2015;348(6230):124-128.
Rizvi NA, et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer. Science. 2015;348(6230):124-128.
Kim JM, Chen DS. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Ann Oncol. 2016;27(8):1492-1504.
Kim JM, Chen DS. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Ann Oncol. 2016;27(8):1492-1504.
Goodman AM, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017;16(11):2598-2608.
Goodman AM, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017;16(11):2598-2608.
Learn more about the importance of oncologic biomarkers and what they can tell you.
Learn more about how cancer avoids immune response.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.